Compare GF & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GF | NYXH |
|---|---|---|
| Founded | 1990 | 2009 |
| Country | Germany | Belgium |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.9M | 188.1M |
| IPO Year | N/A | 2021 |
| Metric | GF | NYXH |
|---|---|---|
| Price | $11.50 | $4.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $12.67 |
| AVG Volume (30 Days) | ★ 28.1K | 27.6K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 0.82% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,616,215.00 |
| Revenue This Year | N/A | $75.27 |
| Revenue Next Year | N/A | $277.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 10.96 |
| 52 Week Low | $7.38 | $4.35 |
| 52 Week High | $9.41 | $11.87 |
| Indicator | GF | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 61.97 | 43.28 |
| Support Level | $11.28 | $4.47 |
| Resistance Level | $11.54 | $4.86 |
| Average True Range (ATR) | 0.17 | 0.19 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 91.84 | 18.21 |
NEW GERMANY FUND INC is a non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investment includes investments in different sectors such as the industrials, information technology, material, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.